MUNICH, September 14, 2016 /PRNewswire/ --
This material is intended for global medical media only.
For journalistic assessment and preparation before publication.
Results from a post hoc analysis of the three-year part of the phase 3a SCALE
and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial show that
people treated with Saxenda(R) (liraglutide 3 mg) experienced consistent weight loss
improved blood glucose control across baseline body mass index (BMI) categories over
years as compared to placebo treatment. These data were presented today at the 52nd
Meeting of the European Association for the Study of Diabetes (EASD) 2016.
In the trial, adults with prediabetes and obesity or who were overweight with
comorbidities were randomised to receive Saxenda(R) (n=1,505) or placebo (n=749) for
weeks, both as an adjunct to a reduced-calorie diet and increased physical activity.1
"Treating obesity and related comorbidities can be complex and challenging," said
Professor Sten Madsbad, clinical professor at the University of Copenhagen and a SCALE
clinical trial investigator. "It is encouraging to now have three-year data
that, regardless of starting BMI, people in the trial experienced consistent weight
and improvements in several measures of glycaemic control."
As part of this analysis, measures of blood glucose control and the overall safety
profile across baseline BMI categories in people treated with Saxenda(R) vs placebo
assessed. These baseline BMI categories were classified as; overweight: BMI 27-29.9
obesity class 1: BMI 30-34.9 kg/m2, obesity class 2: BMI 35-39.9 kg/m2 and obesity
and over: BMI greater than or equal to40 kg/m2. People treated with Saxenda(R)
consistent weight loss across all BMI categories: 5.7%, BMI 27-29.9 kg/m2; 6.5%, BMI
30-34.9 kg/m2; 6.2%, BMI 35-39.9 kg/m2; 5.9%, BMI greater than or equal to40 kg/m2
compared to 1.8%, 1.7%, 1.8% and 2.1% in the same categories with placebo treatment.
percentage of individuals who reverted to normal blood glucose levels at 160 weeks on
Saxenda(R) was also similar at: 67%, 67%, 70% and 63%, respectively, in each of the
BMI categories and significantly greater compared to 36%, 34%, 40% and 33%,
with placebo (p